QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 180-life-sciences-granted-european-patent-ep3265107-for-treating-dupuytrens-disease-using-tnf-receptor-2-antagonist

https://register.epo.org/application?number=EP16759326

 180-life-sciences-reports-positive-topline-results-of-a-clinical-pharmacology-study-testing-a-new-solid-formulation-of-cbd-with-enhanced-oral-uptake-twelve-volunteers-received-all-three-formulations-in-a-crossover-randomized-trial

180 Life Sciences Corp. (NASDAQ:ATNF) ("180 Life Sciences" or the "Company"), today announced topline results f...

 180-life-sciences-granted-an-additional-extension-by-nasdaq-hearing-panel-to-regain-compliance-with-continued-listing-requirements

180 Life Sciences Corp. (NASDAQ:ATNF) ("180 Life Sciences" or the "Company"), today announced that it received ...

 180-life-sciences-granted-extension-by-nasdaq-hearing-panel-to-regain-compliance-with-continued-listing-requirements

- SEC Filing

 180-life-sciences-says-james-n-woody-resigned-as-ceo-and-as-board-member-on-may-7-2024

On May 7, 2024, Dr. Jonathan Rothbard resigned as Chief Scientific Officer of the Company

 180-life-sciences-regains-full-compliance-with-nasdaq-minimum-bid-price-requirement

180 Life Sciences Corp. (NASDAQ:ATNF) ("180 Life Sciences" or the "Company"), today announced that the Company ...

 180-life-sciences-to-conduct-reverse-stock-split-of-its-outstanding-shares-of-common-stock-at-1-for-19-ratio

The Reverse Stock Split is expected to become effective on February 28, 2024 at 12:01 p.m. Eastern Time, with shares expected t...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION